Pfizer’s Beqvez approved by FDA for haemophilia B treatment
Betsy Goodfellow | April 29, 2024 | News story | Medical Communications | FDA, Haematology, Pfizer, haemophilia
Pfizer has announced that the US Food and Drug Administration (FDA) has approved Beqvez (fidanacogene elaparvovec-dzkt) for the treatment of adults with moderate to severe haemophilia B.
The drug is approved for patients with haemophilia B who ‘currently use factor IX (FIX) prophylaxis therapy, or have current or historical life-threatening haemorrhage, or have repeated, serious spontaneous bleeding episodes, and do not have neutralising antibodies to adeno-associated virus serotype Rh74var (AAVRh74var) capsid as detected by an FDA-approved test’, according to the company’s press release.
Beqvez is a one-time treatment which aims to enable patients to produce FIX themselves, compared to the current standard-of-care which includes several intravenous infusions of FIX administered regularly.
Aamir Malik, chief US commercial officer and executive vice president at Pfizer, commented: “This milestone is a testament to Pfizer’s continued effort to advance the standard of care for people living with haemophilia, with the delivery of a medicine that has the potential to offer both long-term bleed protection and value to the healthcare system because of its one-time administration. We are leveraging our expertise that comes with more than 40 years of experience in the haemophilia space, and are proactively working with treatment centers, payers and the haemophilia community to appropriately help ensure the healthcare system is prepared to readily deliver Beqvez to the patients who can benefit from it.”
Kim Phelan, chief operating officer at The Coalition for Hemophilia B, added: “For people living with haemophilia, disease management can interfere with many aspects of their lives. A one-time infusion of Beqvez may allow eligible patients more time for the things they love. We are excited to have Beqvez as a promising treatment option for eligible people living with haemophilia B. We look forward to learning more and celebrating with the community and with Pfizer at our annual conference that is currently taking place.”
Betsy Goodfellow
Related Content
FDA approves Roche’s HPV self-collection screening option
Roche has announced that the US Food and Drug Administration (FDA) has approved its human …
NHS accepts Pfizer’s tafamidis for ATTR-CM treatment
NHS England has announced that it has accepted Pfizer’s drug, tafamidis, for the treatment of …
Moderna shares update on RSV vaccine
Moderna has announced that the US Food and Drug Administration (FDA) has shared that it …
